Table 5.
Adverse effects of systemic treatment
| Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | Grade 4 n (%) | |
|---|---|---|---|---|
| Haematological | ||||
| leukopenia | 42 (27) | 8 (5) | 1 (1) | |
| neutropenia | 42 (27) | 8 (5) | 1+1 | |
| thrombocytopenia | 33 (21) | 11 (7) | (1+1)* | |
| anaemia | 88 (57) | 10 (6) | ||
| Non-haematological | ||||
| alopecia | 62 (40) | 21 (14) | / | / |
| fatigue | 93 (60) | 11 (7) | 0 | / |
| nausea | 40 (26) | 10 (6) | 0 | / |
| vomiting | 14 (9) | 9 (6) | 0 | 0 |
| diarrhea | 23 (15) | 29 (19) | 2 (2) | 1 (1) |
| stomatitis | 4 (3) | 2 (2) | 0 | 0 |
| hand-foot syndrome | 17 (11) | 6 (4) | 0 | / |
| peripheral sensory neuropathy | 32 (21) | 8 (5) | 0 | 0 |
| hepatic toxicity | 17 (11) | 3 (2) | 0 | 0 |
| renal toxicity | 0 | 0 | 1 (1) | 0 |
| acneiform rash | 14 (9) | 38 (25) | 0 | 0 |
| hypermagnesemia | 6 (4) | 0 | 3 (2) | 0 |
| allergic reaction to cetuximab | 3 (2) | 1 (1) | 0 | 0 |
| allergic reactions to oxaliplatin | 1 (1) | 0 | 0 | 0 |
| arterial hypertension | 3 (2) | 9 (6) | 0 | / |
| proteinuria | 20 (13) | 18 (12) | 0 | 0 |
| bleeding | 6 (4) | 0 | 1 (1) | |
| thromboembolic events | 0 | 7 (5) | 0 | 0 |
| wound complications | 0 | 0 | 0 | / |
| perforation | 0 | 0 | 0 | 0 |
| arthralgia | 17 (11) | 2 (2) | 0 | 0 |
| bladder infection | / | 3 (2) | 0 | 0 |
*
1 patient had febrile neutropenia; / = this grade of adverse effect does not exist; 0 = this grade of adverse effect was not observed in our study